

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: :  
Robert G. Aslanian et al :  
:   
For Patent For: Examiner: To be assigned  
Novel Non-Imidazole Compounds :  
Art Unit: To be assigned  
Serial No.: To be assigned :  
Filing Date: To be assigned :  
-----X

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98.  
Applicants enclose a Form PTO-1449 (one page) listing publications known to  
applicants that may be relevant to this application.

This Statement accompanies the divisional application on filing.


Publications AA-AH, AL-AO and AQ-AY were cited either in the background portion  
of the specification or in the examples. It is noted that AV is an English abstract of a  
Hungarian journal article referred to in the application. Publications AP, AZ and BQ  
were cited during the prosecution of the parent application. Publication BL on the  
attached PTO Form-1449 is the published PCT equivalent of reference cited as AZ  
in the parent application.

Publications AI, AJ, and AK are later-filed, co-owned, co-pending US applications,  
none of which have been published at this date.

Copies of newly cited AI, AJ, AK and BL are provided. Copies of the remaining  
references are not provided since they should be available in the file of the parent  
application. The examiner is requested to contact the undersigned attorney if copies  
of any of the references are not available.

The examiner is requested to examine the publications, to initial the form PTO-1449 and to return a copy of the initialed form to applicants.

Respectfully submitted,

  
\_\_\_\_\_  
Anita W. Magatti  
Reg. No. 29,825  
Attorney for Applicants  
(908) 298-5067

10/31/03

Date

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: AL01348K1B	SERIAL NO.: To be assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>				APPLICANT: Robert G. Aslanian et al.	
				FILING DATE: To be assigned	GROUP: To be assigned

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA	5,869,479	02/09/99	William Kreutner et al.	514	212	
	AB	5,463,074	10/31/95	Neng-Yang Shih et al.	548	314.7	
	AC	5,578,616	11/26/96	Robert G. Aslanian et al.	514	341	
	AD	5,633,250	05/27/97	Neng-Yang Shih	514	218	
	AE	5,807,872	09/15/98	Neng-Yang Shih et al.	514	326	
	AF	5,990,147	11/23/99	Robert G. Aslanian	514	400	
	AG	6,034,251	03/07/00	Robert G. Aslanian et al.	548	338.1	
	AH	6,100,279	08/08/00	Wayne D. Vaccaro et al.	514	326	
	AI	10/417,391	Filed 4/16/03	Zeng et al			
	AJ	10/414,943	Filed 4/16/03	Ting et al			
	AK	10/600,674	Filed 6/20/03	Aslanian et al			

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
					YES	NO	
AL	WO 95/14007	26/05/95	WIPO				
AM	WO 99/24405	20/05/99	WIPO				
AN	WO 98/06394	19/02/98	WIPO				
AO	0 407 217 A1	06/07/90	EPO				
AP	WO 97/19074	5/29/97	WIPO				
BL	WO 02/072570	9/19/02	WIPO				

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
AQ	European Journal of Pharmacology Vol. 294 (1995) 329-335
AR	The Journal of Organic Chemistry, Vol. 33, No. 6, June 1968, pgs. 2388-2392
AS	Journal of Medicinal Chemistry, Vol. 19, 1976, pgs. 360-365
AT	J. Heterocyclic Chem., 3 (1960) pgs. 252-256
AU	Journal of Medicinal Chemistry, 37(16), (1994), pgs. 2537-2551
AV	T. Zsuzsanna, Hung. Magy. Kem Foly. 74(3) (1968) pgs. 116-119
AW	Journal of Medicinal Chemistry, 43(12), (2000), pgs. 2362-2370
AX	Arch. Pharm. Pharm. Med. Chem. 332 (1999), pgs. 389-398
AY	Arch. Pharm. Pharm. Med. Chem. 331 (1998), pgs. 395-404
AZ	Leurs et al, TIPS, Vol. 19, May 1998, pgs. 177-183.
BQ	Bakker et al, Clin. Allergy Immuno., Vol. 17 (2002), pgs. 27-64.

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.